Selected article for: "case report and κ case"
Author: Vechi, Hareton Teixeira; Maia, Lucas Rodrigues; Alves, Manoela do Monte; Rodrigues-Neto, João Firmino
Title: Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report
  • Cord-id: d0etxm4b
  • Document date: 2020_12_18
    • ID: d0etxm4b
    Snippet: COVID-19 is a viral disease caused by SARS-CoV-2 that compromises the host immune response in severe cases, promoting a hyperinflammation that results in acute lung injury and multiple organs failure. In this context, patients presenting with immune-related diseases, such as Crohn’s disease, affected by COVID-19, may have an uncertain prognosis. We report on a case of a young female patient with a severe Crohn’s disease that presented with COVID-19 pneumonia and a favorable outcome even main
    Document: COVID-19 is a viral disease caused by SARS-CoV-2 that compromises the host immune response in severe cases, promoting a hyperinflammation that results in acute lung injury and multiple organs failure. In this context, patients presenting with immune-related diseases, such as Crohn’s disease, affected by COVID-19, may have an uncertain prognosis. We report on a case of a young female patient with a severe Crohn’s disease that presented with COVID-19 pneumonia and a favorable outcome even maintaining the use of adalimumab, TNF - alpha inhibitor and prednisone. This case raises the hypothesis that aside from prednisone, TNF-α inhibitors such as adalimumab could be used to stop the progression to COVID-19 complications by blocking the TNF-alpha-driven inflammatory process that occurs in severe COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome and lung abnormality: 1, 2
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung pneumonia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute kidney injury and long duration: 1
    • acute kidney injury and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute kidney injury and lung damage: 1, 2, 3, 4, 5, 6
    • acute kidney injury and lung pneumonia: 1, 2, 3, 4, 5, 6, 7
    • acute pulmonary injury and long duration: 1
    • acute pulmonary injury and low mortality: 1
    • acute pulmonary injury and lung damage: 1, 2, 3, 4, 5, 6, 7
    • acute pulmonary injury and lung pneumonia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory distress syndrome and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung abnormality: 1, 2, 3, 4
    • acute respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung pneumonia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome development and long duration: 1
    • acute respiratory distress syndrome development and lung pneumonia: 1, 2, 3, 4